Volume 82, Issue 6 pp. 838-843
Original Article

Chemerin and prediction of Diabetes mellitus type 2

Thomas Bobbert

Corresponding Author

Thomas Bobbert

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Correspondence: Thomas Bobbert, Charité, Department of Endocrinology, Diabetes and Nutrition, Charitéplatz 1, 10117 Berlin, Germany. Tel.:+49/30/450-514252; Fax: +49/30/450-514950; E-mail: [email protected]Search for more papers by this author
Franziska Schwarz

Franziska Schwarz

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany

Search for more papers by this author
Antje Fischer-Rosinsky

Antje Fischer-Rosinsky

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany

Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany

Search for more papers by this author
Lukas Maurer

Lukas Maurer

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany

Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany

Search for more papers by this author
Matthias Möhlig

Matthias Möhlig

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Search for more papers by this author
A.F.H. Pfeiffer

A.F.H. Pfeiffer

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Department of Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany

Search for more papers by this author
Knut Mai

Knut Mai

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany

Search for more papers by this author
Joachim Spranger

Joachim Spranger

Department of Endocrinology, Diabetes and Nutrition, Charité-Universitätsmedizin Berlin, Berlin, Germany

Charité Center for cardiovascular Research (CCR), Charité-Universitätsmedizin Berlin, Berlin, Germany

Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin and Max-Delbrück Zentrum, Berlin-Buch, Germany

Search for more papers by this author
First published: 30 January 2015
Citations: 31

Summary

Objective

Insulin resistance and subclinical inflammation are characteristics in the development of type 2 diabetes mellitus (T2DM). The adipokine chemerin has been associated with both factors. The aim of this study was to analyse whether chemerin predicts T2DM.

Design

Blood samples of 440 participants of the Metabolic-Syndrome Berlin-Potsdam (MesyBepo) follow-up study without diabetes at baseline were available for chemerin measurement. Mean follow-up of participants was 5·3 years. Glucose metabolism was analysed using oral glucose tolerance test including insulin measurements. Chemerin was measured using a commercially available ELISA.

Results

Thirty-five individuals developed T2DM during follow-up. Chemerin predicted incident T2DM (Chemerin 1. Tertile: reference, 2. Tertile: OR 2·33 [0·68–7·95]; Chemerin 3. Tertile: OR 3·42 [1·01–11·58] after adjustment for age, sex, BMI, follow-up time, HbA1c, HOMA-IR and WHR). In a secondary analysis, chemerin also predicted worsening of fasting glucose and HbA1c (adjusted for age, sex, BMI, time of follow-up, WHR, HDL cholesterol and triglycerides).

Conclusions

Our data suggest that chemerin is a weak predictor of T2DM.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.